abstract |
The invention relates to the field of psychoneurology and, in particular, to agents for treating multiple sclerosis. The composition (a solid oral dosage form) contains (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethyl-phenyl)-amide (Teriflunomide) as active principle. |